Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.
Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Thermo Fisher (TMO) rides high in Q2 banking on its analytical instruments segment in particular.
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
The ongoing political conflict resulting in a delay in policy implementation is a major dampener for Q2 earnings in the Medical space.
Thermo Fisher Scientific Inc. (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.
Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.